~//bj.watch/overview
live

Latest signal

last curated pass Nov 12, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets

# all # health # longevity # nutrition # sleep # concepts

Recent curated signals

Ideology “It’s all hands on deck for the human race and NVIDIA needs its founder at the helm”: a one-sentence, same-day reaction to the biggest AI-industry news event of the quarter — Jensen Huang resigned as NVIDIA’s President and CEO the morning of the post — and the feed’s first direct entry into the AI-leadership news cycle, currently its most-liked audited post since the November 5 market meme Johnson posted a single sentence with no link and no image: “It’s all hands on deck for the human race and NVIDIA needs its founder at the helm.” (11,964 likes, 382 reposts, 277 replies; November 12, 16:17 UTC). The referent verifies as same-day news: NVIDIA’s board announced that morning that Jensen Huang had resigned as President, Chief Executive Officer, and board member, effective immediately, with CFO Colette Kress appointed interim CEO and Harvey C. Jones the board’s first-ever chair (NVIDIA newsroom, November 12, 2026); same-day wire coverage (AP, Reuters, BBC) reports the resignation followed disclosures of extramarital relationships — one involving a woman U.S. intelligence reportedly suspects of being a Chinese government agent, raising national-security concerns and lawmaker calls for testimony — with roughly $550 billion of market value lost in the five days before the resignation, and AP noting it could not independently confirm parts of the reporting. Read against that record, the post is a same-day defense of the departed founder; read against the feed’s own ideology, its framing is the Don’t Die superintelligence-era survival narrative applied to an AI-compute leadership crisis — the October 6 manifesto’s “gave birth to superintelligence and figured out they’d no longer die” thesis, in which humanity’s task is surviving the transition, making the helm of the era’s compute engine a species-level concern. The post itself names no event and no person, and makes no argument — the attribution is the dashboard’s, not the post’s. The engagement is the notable measurable: 11,964 likes at re-read (~02:40 UTC, November 13) — the third-highest count in the 30-post audit window behind only the two November 5 memes, and the most-liked audited post since the November 5 market meme. Boundaries: the post makes no health claim; “needs its founder at the helm” is an opinion, not a claim about NVIDIA’s governance or Huang’s conduct; the relationship and national-security reporting remains contested and under congressional scrutiny; nothing here is medical advice — the dashboard records an attributed ideology-flavored reaction to a verified same-day event. Reception “At least one billionaire per week reaches out to me”: the feed’s first quantified adoption-rate claim for Don’t Die protocols — an unverifiable private-inbound self-report with no names, count, or baseline, wrapped in a passion → business → lower costs → accessibility theory of change that is a forecast, not a mechanism in evidence Johnson posted the feed’s first quantified adoption-rate claim for the movement: “At least one billionaire per week reaches out to me to learn how to set up their own Don’t Die protocol. It’s the new norm. / This is good news because personal passion will turn into business interests which will lower the costs and increase accessibility for everyone.” (1,094 likes, 25 reposts, 83 replies; November 12, 19:18 UTC, with a photo). The claim is a private-inbound self-report: no billionaire is named, no cumulative count, no time window beyond “per week,” no baseline, and no way to distinguish protocol inquiry from casual contact — the same unverifiable-inbound class as the feed’s earlier reception claims. The storyline context is real: the adoption-and-status arc the dashboard already tracks (the October 7 “health is the new status” thesis, the October 8 Axios validation and Mike Solana life-extension musing) here moves from status signaling to a claimed inquiry pipeline with a rate attached. The second paragraph is a theory of change — personal passion becomes business interest, which lowers costs and increases access — that matches how Johnson describes his own commercial stack (Blueprint marketplace, Immortals), but the post contains no protocol, price, or access figure: the cost-and-accessibility outcome is a forecast, not evidence. Boundaries: the attached photo was not vision-verified and no dashboard claim depends on it; “It’s the new norm” is a perception claim; billionaire interest, even if exactly as frequent as claimed, is not evidence that Don’t Die protocols improve health, that costs will fall, or that anything is becoming accessible to anyone. The dashboard records an attributed adoption self-report with verified storyline context — not evidence of efficacy, adoption at scale, or medical advice. Methodology “MRI brain-age clocks plus genomics, proteomics, and metabolomics”: a methodology post that matches the published brain-aging literature almost exactly — MRI brain-age gaps paired with plasma omics is a real, active research program whose top associated protein is GDF-15, the very marker Johnson has been measuring after workouts — but the post names no program, partner, or result, and “proteins and metabolites driving accelerated brain aging” claims a causation the correlational literature does not Johnson posted a brain-aging measurement roadmap: “Slowing brain aging is one of the hardest things to solve. / The first step is to understand the specific proteins and metabolites driving accelerated brain aging. / MRI brain-age clocks plus genomics, proteomics, and metabolomics identifies molecular correlates.” (342 likes, 7 reposts, 37 replies; November 12, 22:22 UTC, with a figure image). The methodology verifies against the published field: MRI-derived brain-age prediction — the gap between predicted and chronological brain age — is an established research tool, and pairing imaging brain-age gaps with plasma omics is an active program (the review literature frames exactly this epigenetic-, proteomic-clock-plus-neuroimaging stack). In the ARIC cohort (n = 1,849; 4,877-protein SOMAscan), 33 proteins were associated with the MRI brain-age gap after correction, with GDF-15 the top positive association — the same growth-factor biomarker Johnson has been self-measuring after dunk-training workouts (the November 4 GDF15 post), here emerging as the literature’s strongest circulating correlate of MRI-measured brain aging. At population scale, UK-Biobank-trained organ-specific proteomic clocks (43,616 participants, validated in Chinese and U.S. cohorts) find brain aging the organ-aging measure most strongly linked to mortality. Boundaries: the post names no program, team, device, partner, dataset, or result — it is a direction, not a finding; the attached figure image was not vision-verified and no dashboard claim depends on it; “driving” overstates the correlational evidence — association studies identify molecular correlates (the post’s own last word), not causes; and the field’s own reviews name biomarker-standardization and longitudinal-validation gaps before any clinical use of brain-age clocks. The dashboard records an attributed methodology post with verified literature context — not a named research program, a validated brain-age service for readers, or medical advice. Media The feed’s first pure meme-participation post — a thirteen-item answer to Greg Isenberg’s viral “Status symbols today” list that compresses a year of tracked storylines into a checklist (“a side quest (dunking)”, “ice on boys in sauna”, “shrooms as longevity medicine”) — making no claim, publishing no data, and performing the October 7 “health is the new status” thesis as an in-joke Johnson quote-posted Greg Isenberg’s same-hour viral list “Status symbols today” — a catalogue of contemporary status markers already containing “Knowing your VO2 max, DEXA stats, and ApoB”, “Caring about microplastics”, “Talking about cold plunges”, and “Custom cedar sauna + outdoor shower in the backyard” (3,191 likes, 206 reposts, 161 replies; November 12, 19:03 UTC) — with a thirteen-item counter-list of his own: “a low resting heart rate / high quality skin / prioritizing sleep / good posture / wearing ear plugs at social events / ice on boys in sauna / having a side quest (dunking) / interested in your girls health / open minded to not dying / sun damage aware / eliminating microplastics in balls / shrooms as longevity medicine / moderating international travel” (610 likes, 24 reposts, 30 replies; 23:46 UTC, with three photos). Nothing in the post is a claim to verify; nearly every line is a compressed reference to a storyline the dashboard already tracks — the “Sovereignty Index” resting-heart-rate framing, the October 22 earplugs directive, the October sauna equipment disclosure, the dunk side quest, the Kate Tolo female-protocol program, Don’t Die itself, the microplastics-in-semen claims, the November 9 psilocybin anniversary and October psilocybin-Parkinson’s relay, and the June one-international-trip-per-quarter rule. The post is the October 7–8 “health is the new status” thesis rendered as participation: Isenberg’s list already ranks biomarker knowledge among the status symbols, and Johnson answers by converting his protocol into a status checklist — the same mechanism the dashboard recorded when Axios validated the framing. Boundaries: a joke-format post with no data, no measurement, and no argument; the referenced items are personal practices previously recorded as attributed N=1 claims, not validated interventions; psilocybin remains a Schedule I controlled substance outside regulated research, and “shrooms as longevity medicine” is a meme line, not evidence; the three attached photos were not vision-verified and no dashboard claim depends on them. The dashboard records an attributed media-participation post with a decoded reference trail — not a claim set, a protocol recommendation, or medical advice. Research claim “Lifting weights 3x a week while taking a GLP-1 preserved muscle, had double digit strength gains, and got rid of fat”: the feed’s most exactly verified research relay to date — every claim maps number-for-number onto the T-REx randomized trial published the same morning, with one substitution the post doesn’t make (tirzepatide, not “a GLP-1”) and one beneficiary left unstated (the fat loss is the drug’s, not the lifting’s) Johnson relayed a same-day randomized trial in three sentences: “Lifting weights 3x a week while taking a GLP-1 preserved muscle, had double digit strength gains, and got rid of fat. / Lifting + GLP-1s FTW.” (2,905 likes, 103 reposts, 139 replies; November 11, 20:27 UTC, with a study-figure image). The post names no study, but every line traces to the T-REx trial — “Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial,” Nature Medicine, November 11, 2026 (10.1038/s41591-026-04752-5): 120 adults aged 50–70 with overweight or obesity (no type 2 diabetes) treated with tirzepatide and randomized to thrice-weekly resistance exercise or usual activity for 40 weeks (91% exercise adherence). Each claim verifies number-for-number: “preserved muscle” — total lean soft-tissue loss −3.57 kg with training vs −4.67 kg without (between-group difference 1.09 kg, 95% CI 0.43–1.75, P < 0.001), roughly 24% less lean loss (the university release rounds to 25%); “double digit strength gains” — bench press +10.7%, lat pulldown +15.7%, knee extension +17.5% in the training arm vs declines of 8.4%, 6.5%, and 9.0% without it (all P < 0.001), so the phrase is exact on all three lifts; “got rid of fat” — fat-mass loss was statistically identical between arms (−17.98 vs −17.19 kg, P = 0.700), which verifies the outcome while quietly attributing it to the drug rather than the lifting. Boundaries: the drug is tirzepatide, a GIP/GLP-1 receptor agonist, not semaglutide or “a GLP-1” in general; participants were adults 50–70 with obesity — not Johnson’s regimen or his audience’s baseline; lean soft tissue by DXA is not muscle quality or function; the trial was investigator-initiated with free manufacturer medication but no manufacturer role in design, implementation, or evaluation; and Johnson’s Immortals Rx sells GLP-1 medications, the same commercial adjacency the dashboard records on his September semaglutide mouse-lifespan relay. The dashboard records an attributed research relay with an exactly verified source — not a reader exercise prescription, medication guidance, or medical advice. Research claim “LSD as a longevity therapy?”: a same-morning Aging Cell paper does say LSD pushed rat brain gene activity opposite to human aging — and beat exercise, but only on a transcriptomic reversal ratio; the entire evidence base is rats, mice, and cultured neurons, with zero human results and a Schedule I boundary the post never mentions Johnson posted a psychedelics-and-aging research relay: “LSD as a longevity therapy? / LSD pushes brain gene activity in the opposite direction of aging / In rodents, the effect was stronger than exercise / LSD activated gene networks involved in neuroplasticity and neuronal communication, and reduced amyloid-β damage” (1,250 likes, 116 reposts, 127 replies; November 11, 19:01 UTC, with a study-figure image). The post names no study, but every line traces to one paper published the same morning — Savino, Liaci, Bertani, … Iorio, “Lysergic acid diethylamide reverses aging- and neurodegeneration-associated brain transcriptional programs,” Aging Cell, November 11, 2026 (10.1111/acel.70793; preprint 10.64898/2026.05.26.727809, Human Technopole Milan). Claim-by-claim: “opposite direction of aging” verifies — chronic LSD treatment in the rat medial prefrontal cortex produced gene-expression changes significantly anti-correlated with age-ranked genes across integrated human prefrontal-cortex datasets (3,086 samples spanning ages 2 days to 106 years; Fisher-aggregated p < 2.2 × 10⁻³⁰⁸ for upregulated genes), reproducible across datasets and species. “Stronger than exercise” is true but narrower than it reads: on the paper’s age-reversal p-value ratio, chronic LSD scored highest (average apr = 198) against exercise and enriched-environment positive controls (largest average apr = 136) — a property of transcriptomic signatures, not of brains, bodies, or longevity outcomes. “Activated gene networks involved in neuroplasticity and neuronal communication” verifies — synapse- and dendrite-related GO categories, typically downregulated with aging, were enriched among LSD-upregulated genes. “Reduced amyloid-β damage” verifies in vitro — in primary cortical neurons exposed to 100 nM amyloid-β, subsequent LSD restored MAP2-positive dendritic arborization that amyloid-β had damaged, without affecting architecture on its own. Boundaries: the entire evidence base is preclinical — rats, mice, and cultured neurons; the paper’s own evidence record shows zero human LSD results; the authors name the bulk-tissue limitation themselves (postmortem bulk tissue mixes cell types whose proportions change with age, so single-cell data will be needed); signature reversal is a computational drug-repurposing rationale, not demonstrated slowing of brain aging or cognitive decline; the post names no study; and LSD remains a Schedule I controlled substance in the U.S. outside regulated research and approved access paths. The dashboard records an attributed research relay with a verified same-day source — not evidence that LSD is a longevity therapy, a recommendation, or medical advice. Measurement “My blood glucose is lower than 99.8% of humans”: the feed’s first glucose-percentile claim — the HbA1c/mean-glucose pair is internally consistent under the standard translation (4.6% ↔ eAG 85 vs a claimed 79 mg/dL), and the rust metaphor matches real glycation pathology, but the mortality curve’s own “basement” sits at ~5.5%, 0.9 points above him, and “99.8% of humans” is measured against the world’s diabetic population, not healthy peers Johnson posted the feed’s first glucose-percentile claim: “My blood glucose is lower than 99.8% of humans / best month I’ve had: / > mean 79 mg/dL / > best week 77 mg/dL / > HbA1c 4.6% / Elevated blood glucose rusts from within.” (424 likes, 12 reposts, 80 replies; November 10, 19:16 UTC, with a photo). The internal arithmetic is consistent under the standard translation: the ADAG study (Nathan et al., Diabetes Care 2008; 507 subjects; eAG = 28.7 × A1C − 46.7) puts HbA1c 4.6% at an estimated average glucose of 85.3 mg/dL — within the regression’s ±15.7 mg/dL prediction error of the claimed 79 mg/dL CGM month mean, which back-translates to ~4.4% A1c. But the translation at this end is an extrapolation: Labcorp’s reporting guidance calculates eAG only for HbA1c 5.0–15.0% because “estimations in the nondiabetic range have not been verified,” and a CGM interstitial average is not venous plasma. “Elevated blood glucose rusts from within” works as a glycation metaphor: elevated glucose accelerates nonenzymatic glycation and advanced glycation end-product (AGE) formation, and the AGE–RAGE axis generates reactive oxygen species and inflammatory cascades central to diabetic complications (Nature Reviews Endocrinology 2008, ncpendmet0786) — pathology demonstrated at diabetic-range glucose, not a linear dose–response into the low-normal range. The mortality direction verifies with the stop the post doesn’t mention: EPIC-Norfolk found HbA1c continuously associated with cardiovascular disease and mortality across the nondiabetic distribution, lowest rates below 5% (Khaw et al., BMJ 2001; Ann Intern Med 2004, 10.7326/0003-4819-141-6-200409210-00006), but the cohort’s own 11.2-year reanalysis of 17,196 nondiabetic adults (Diabetologia 2011, 10.1007/s00125-011-2162-0) found the all-cause-mortality hazard “virtually constant in the low range,” rising only above approximately 5.5% — a “basement” below which no mortality benefit of further lowering was demonstrated, and his 4.6% sits 0.9 points below it. Boundaries: “99.8% of humans” is against an unnamed cohort that includes the world’s diabetic and prediabetic population, not healthy peers — the same unpublished-percentile pattern as the Prenuvo and Kernel readouts; the three numbers are summary figures with no device, dataset, or method published; and clinically low HbA1c can also reflect shortened red-cell lifespan (hemolysis, blood loss, anemia) rather than superior metabolic health. The dashboard records an attributed N=1 metabolic readout with verified eAG arithmetic and epidemiologic context — not evidence that pushing HbA1c below 5% extends life, a reader glucose target, or medical advice. Media The feed’s first zero-text post — nine caption-less photos in four seconds, dropped on the one-year anniversary of the live-documented 5 g psilocybin trip and decoded by the thread’s own replies (“You did P. Cubensis”; “its been a year?”) — a memorial that makes no claim and publishes no data Johnson posted an item with no text at all — no caption, no figures, no emoji, rare in the audited record: nine caption-less photos, a root post plus eight self-replies all timestamped within four seconds (20:50:11–20:50:15 UTC, November 9; root: 581 likes, 11 reposts, 33 replies; chain replies 31–71 likes each). The decode comes from the thread itself and the calendar: replies answer the photos with “its been a year? bro what?” and “You did P. Cubensis” — and November 9–10, 2026 is one year after the live-documented psilocybin trip of November 9–10, 2025, when Johnson took 4.67 g dried Psilocybe cubensis (B+ strain, 24.9 mg psilocybin) “under medical supervision, in a legal setting, and with a professional facilitator,” had the experience live-posted by Kate Tolo as trip-sitter, and followed with a trip report (“I felt like a kid finding and exploring a new playground”) and a brain-activity data post, telling curious readers to “speak with your doctor” (Daily Mail, November 11, 2025; LADbible, November 10, 2025; his own November 18, 2025 recap). The original announcement said he would dose once a month for three months to study longevity effects; no published biomarker readout of that series ever appeared, and today’s drop adds none — no text, no claim, no measurement, just the images. Boundaries: the dashboard cannot independently describe the nine photos (no vision verification was performed); the anniversary decode rests on reply context plus timing; psilocybin remains a Schedule I controlled substance in the U.S. outside regulated research and state-regulated access, and his original framing — supervision, legal setting, facilitator, talk to your doctor — is the responsible boundary a zero-text memorial quietly drops; the site’s prior psilocybin coverage is the October Parkinson’s-GDF15 research relay, not personal-use advocacy. The dashboard records an attributed media drop with verified anniversary context — not a recommendation, evidence of benefit, new data, or medical advice.

// Reference paths

Move from feed to dossiers

Each route keeps source trails and medical caution visible.
Protocol Health

Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.

 Protocol Longevity

Habits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.

 Protocol Nutrition

Habits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.

 Protocol Sleep

Habits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.

 Reference Concepts

39 source-aware glossary entries, including concepts without dedicated wiki pages yet.

 entity Blueprint

Blueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer

 concept Blueprint Protocol

The Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a

 concept Don't Die

Don't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a

 concept Biomarker-driven longevity protocols

A biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre

 Signal Metrics

Inspect source velocity by range, content type, and fallback API state.